The frequency of simultaneous mutations of TP53 with EGFR or KRAS is higher than 5% in both Western and Asian lung adenocarcinoma patients while it is significantly lower in lung squamous cell carcinoma patients of the two major groups.40 Here, TP53 is linked to lung adenocarcinoma.